What's breaking now, across thousands of outlets.
Data from an early trial showed the company’s “gamma delta” cell therapy surpassed benchmarks set by personalized CAR-T treatments tested in lupus.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.
After winning FDA approval at the end of last year, two nonprofits are now launching their rare immune disease gene therapy Waskyra with a list price of $3.25 million, they told Endpoints News.
Depression may be an overlooked factor in cancer outcomes, according to a large SEER-Medicare analysis of more than 265,000 adults with six common cancers.
Marie-Celestin Karondwa was attacked on Sunday after promoting measures to prevent spread of disease, his party says A senior member of the Democratic Republic of the Congo’s ruling party was beaten…
Marie-Celestin Karondwa was attacked on Sunday after promoting measures to prevent spread of disease, his party says A senior member of the Democratic Republic of the Congo’s ruling party was beaten…
BROSSARD, Quebec, Sept. 28, 2026 (GLOBE NEWSWIRE) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of…
